PODD · XBRL financial data

Insulet financial statements, every fiscal year

The same tables from 7 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (PODD's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue	904	1,099	1,305	1,697	2,072	2,708
Revenue from contracts with customers	904	1,099	1,055	—	—	—
Cost of goods and services sold	322	347	500	537	626	768
Gross profit	582	752	806	1,160	1,446	1,940
Research and development	147	160	180	205	220	301
Selling, general and administrative	384	466	588	735	917	1,165
Operating income (loss)	52	126	38	220	309	474
Interest income	—	1	9	29	40	35
Interest expense	48	62	37	36	43	59
Other income (expense)	3	(2)	(1)	2	(6)	14
Income tax expense (benefit)	3	4	5	8	(118)	92
Net income (loss)	7	17	5	206	418	247
Earnings per share, basic USD per share	0.11	0.25	0.07	2.96	5.97	3.51
Earnings per share, diluted USD per share	0.10	0.24	0.07	2.94	5.78	3.48
Weighted average shares, basic millions of shares	65	68	69	70	70	70
Weighted average shares, diluted millions of shares	66	69	70	74	74	72

Fiscal years (PODD's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	907	806	690	704	953	716
Marketable securities	40	0	—	—	—	—
Accounts receivable	84	161	141	—	—	517
Inventory	154	303	347	403	430	453
Prepaid and other current assets	63	74	87	116	142	228
Total current assets	1,249	1,330	1,314	1,583	1,891	1,914
Property and equipment, net	479	537	600	—	—	—
Right-of-use asset	15	10	26	28	37	44
Goodwill	40	40	52	52	52	52
Total assets	1,873	2,049	2,251	2,588	3,088	3,190
Accounts payable	54	38	31	19	20	75
Accrued liabilities	138	166	301	—	—	587
Current portion of long-term debt	16	25	28	49	84	18
Total current liabilities	208	229	365	451	528	680
Long-term debt	1,044	1,249	1,374	—	—	—
Lease liability, non-current	12	8	27	30	40	49
Total liabilities	1,269	1,493	1,775	1,856	1,876	1,675
Retained earnings (accumulated deficit)	(666)	(650)	(584)	(378)	40	287
Total stockholders' equity	604	556	476	733	1,212	1,515
Total liabilities and equity	1,873	2,049	2,251	2,588	3,088	3,190
Common shares outstanding (cover page) millions of shares	66	69	70	70	70	70

Fiscal years (PODD's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	7	17	5	206	418	247
Stock-based compensation	36	34	41	48	69	63
Depreciation and amortization	55	57	63	73	81	90
Net cash from operating activities	84	(68)	119	146	430	569
Purchases of property and equipment	129	112	123	76	125	192
Net cash from investing activities	14	(83)	(191)	(119)	(146)	(223)
Proceeds from issuing common stock	478	0	0	—	—	—
Share repurchases	—	—	—	0	0	60
Net cash from financing activities	606	41	(40)	(14)	(28)	(595)
Net change in cash	708	(116)	(117)	15	249	(237)

SIC 3841 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 3841 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Runway	Quarter
Insulet	535	802	88*	69.4M	—	Q2 FY26 10-QJun 30, 2026
MiniMed Group	207	843	(49)	281.3M	2.3 quarters	Q1 FY27 10-QJul 31, 2026
STERIS	482	1,493	367	97.5M	—	Q1 FY27 10-QJun 30, 2026
Zimmer Biomet Holdings	410	2,177	448*	190.7M	—	Q2 FY26 10-QJun 30, 2026
Baxter International	1,975	2,976	558*	517.3M	—	Q3 FY26 10-QSep 30, 2026
West Pharmaceutical Services	464	875	190*	69.7M	—	Q3 FY26 10-QSep 30, 2026
GE HealthCare Technologies	2,826	5,513	907*	452.1M	—	Q3 FY26 10-QSep 30, 2026
Dexcom	961	1,345	326*	373.0M	—	Q3 FY26 10-QSep 30, 2026
Resmed	1,011	1,415	422	140.7M	—	Q1 FY27 10-QSep 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.